A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer
Status:
Completed
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase III, randomized, active-controlled trial to evaluate the
efficacy and safety of rhuMAb VEGF (Avastin) added to the standard first-line chemotherapy
used to treat metastatic colorectal cancer. This trial will enroll approximately 900 subjects
with histologically confirmed, previously untreated, bi-dimensionally measurable metastatic
colorectal cancer.